0 XP   0   0   0

Nykode Therapeutics ASA










Financial Health of Nykode




Comparing to competitors in the Biotechnology industry




  Industry Rankings  


Nykode Therapeutics ASA
Buy, Hold or Sell?

Should you buy, hold or sell Nykode?

I guess you are interested in Nykode Therapeutics ASA. Buy, hold or sell? I don't know! However, I do recommend doing research before doing anything. I will help you with that.

Let's analyse Nykode

Let's start. I'm going to help you getting a better view of Nykode Therapeutics ASA. At the end you don't have to ask anyone for trading advice. You can make your own decision, with more confidence, the odds in your favor, backed by data.

  1. Company's Financial Health
    A deep dive into the books. How are the numbers doing? Is Nykode Therapeutics ASA even making a profit? Is the company skyrocketing? Or is it sinking like the Titanic. The trend is your friend.
  2. Market Valuation
    Finally, you now have an insight of how Nykode Therapeutics ASA is doing in the market. If the company is worth buying. The latest step is to find out how other investors value Nykode Therapeutics ASA. The closing price on 2022-12-02 was kr27.16 per share. Is the company over- or underpriced?
  3. Key Performance Indicators
    A total overlook on how the company is doing. Based on the (trends in) the key performance indicators.
Nykode Therapeutics ASA Daily Candlestick Chart

Summary

Financial Health

Profitability Details
 Compared to previous yearCompared to industry
The company is making a huge loss.
Using its assets, the company is very inefficient in making profit.
Using its investors money, the company is very inefficient in making profit.
Operating Efficiency Details
 Compared to previous yearCompared to industry
The company is operating very inefficient.
The company is inefficient in keeping operating costs low.
Liquidity Details
 Compared to previous yearCompared to industry
The company is very able to pay all its short-term debts.
The company is very able to pay all its short-term debts with the most liquid assets.
Solvency Details
 Compared to previous yearCompared to industry
The company is very able to pay all its debts by selling its assets.
The company is very able to pay all its debts with equity.

1.1. Profitability of Nykode Therapeutics ASA.

1.1. Profitability
1.1.1. Net Profit Margin

Measures how much net profit Nykode earns for each kr1 of revenue.

  • Above 10% is considered healthy but always compare Nykode to the Biotechnology industry mean.
  • A Net Profit Margin of -2,297.8% means that kr-22.98 for each kr1 in revenue is generated as profit.

Let's take a look of the Net Profit Margin trends of Nykode Therapeutics ASA:

  • The MRQ is -2,297.8%. The company is making a huge loss. -2
  • The TTM is -892.8%. The company is making a huge loss. -2
Trends
Current periodCompared to+/- 
MRQ-2,297.8%TTM-892.8%-1,405.0%
TTM-892.8%YOY-686.3%-206.5%
TTM-892.8%5Y-701.8%-191.0%
5Y-701.8%10Y-701.8%0.0%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-2,297.8%-223.6%-2,074.2%
TTM-892.8%-281.7%-611.1%
YOY-686.3%-344.8%-341.5%
5Y-701.8%-450.1%-251.7%
10Y-701.8%-541.0%-160.8%
1.1.2. Return on Assets

Shows how efficient Nykode is using its assets to generate profit.

  • Above 5% is considered healthy but always compare Nykode to the Biotechnology industry mean.
  • -6.5% Return on Assets means that Nykode generated kr-0.07 profit for each $1 in assets.

Let's take a look of the Return on Assets trends of Nykode Therapeutics ASA:

  • The MRQ is -6.5%. Using its assets, the company is very inefficient in making profit. -2
  • The TTM is -4.1%. Using its assets, the company is very inefficient in making profit. -2
Trends
Current periodCompared to+/- 
MRQ-6.5%TTM-4.1%-2.4%
TTM-4.1%YOY15.0%-19.1%
TTM-4.1%5Y0.4%-4.5%
5Y0.4%10Y0.4%0.0%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-6.5%-9.9%+3.4%
TTM-4.1%-8.9%+4.8%
YOY15.0%-9.3%+24.3%
5Y0.4%-11.7%+12.1%
10Y0.4%-12.7%+13.1%
1.1.3. Return on Equity

Shows how efficient Nykode is using its investors money to generate profit.

  • Above 15%-20% is considered healthy but always compare Nykode to the Biotechnology industry mean.
  • -8.9% Return on Equity means Nykode generated kr-0.09 for each kr1 the owners (shareholders) invested.

Let's take a look of the Return on Equity trends of Nykode Therapeutics ASA:

  • The MRQ is -8.9%. Using its investors money, the company is very inefficient in making profit. -2
  • The TTM is -5.6%. Using its investors money, the company is very inefficient in making profit. -2
Trends
Current periodCompared to+/- 
MRQ-8.9%TTM-5.6%-3.3%
TTM-5.6%YOY19.4%-24.9%
TTM-5.6%5Y1.1%-6.6%
5Y1.1%10Y1.1%0.0%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-8.9%-12.0%+3.1%
TTM-5.6%-11.5%+5.9%
YOY19.4%-10.8%+30.2%
5Y1.1%-14.2%+15.3%
10Y1.1%-15.2%+16.3%

1.2. Operating Efficiency of Nykode Therapeutics ASA.

1.2. Operating Efficiency
1.2.1. Operating Margin

Measures how efficient Nykode is operating .

  • Measures how much profit Nykode makes for each kr1 of sales after paying variable costs (production costs, wages, etc) but before taxes.
  • Above 15% is considered healthy but always compare Nykode to the Biotechnology industry mean.
  • An Operating Margin of -3,071.6% means the company generated kr-30.72  for each kr1 in revenue (before taxes).

Let's take a look of the Operating Margin trends of Nykode Therapeutics ASA:

  • The MRQ is -3,071.6%. The company is operating very inefficient. -2
  • The TTM is -1,140.8%. The company is operating very inefficient. -2
Trends
Current periodCompared to+/- 
MRQ-3,071.6%TTM-1,140.8%-1,930.8%
TTM-1,140.8%YOY-747.6%-393.2%
TTM-1,140.8%5Y-839.3%-301.5%
5Y-839.3%10Y-839.3%0.0%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-3,071.6%-207.3%-2,864.3%
TTM-1,140.8%-271.0%-869.8%
YOY-747.6%-325.9%-421.7%
5Y-839.3%-454.0%-385.3%
10Y-839.3%-537.1%-302.2%
1.2.2. Operating Ratio

Measures how efficient Nykode is keeping operating costs low.

  • Below 1 is considered healthy (always compare to Biotechnology industry mean).
  • An Operation Ratio of 0.00 means that the operating costs are kr0.00 for each kr1 in net sales.

Let's take a look of the Operating Ratio trends of Nykode Therapeutics ASA:

  • The MRQ is 0.000. The data is not here.
Trends
Current periodCompared to+/- 
MRQ-TTM4.457-4.457
TTM4.457YOY8.398-3.941
TTM4.4575Y5.713-1.256
5Y5.71310Y5.7130.000
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-2.871-2.871
TTM4.4573.504+0.953
YOY8.3983.604+4.794
5Y5.7135.132+0.581
10Y5.7136.371-0.658

1.3. Liquidity of Nykode Therapeutics ASA.

1.3. Liquidity
1.3.1. Current Ratio

Measures if Nykode is able to pay off Short-term Debt.

  • Above 1.5 is considered healthy (always compare to Biotechnology industry mean).
  • A Current Ratio of 6.15 means the company has kr6.15 in assets for each kr1 in short-term debts.

Let's take a look of the Current Ratio trends of Nykode Therapeutics ASA:

  • The MRQ is 6.147. The company is very able to pay all its short-term debts. +2
  • The TTM is 7.653. The company is very able to pay all its short-term debts. +2
Trends
Current periodCompared to+/- 
MRQ6.147TTM7.653-1.506
TTM7.653YOY18.516-10.863
TTM7.6535Y12.483-4.830
5Y12.48310Y12.4830.000
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ6.1475.117+1.030
TTM7.6535.755+1.898
YOY18.5165.854+12.662
5Y12.4836.511+5.972
10Y12.4836.222+6.261
1.3.2. Quick Ratio

Measures if Nykode is able to pay off Short-term Debt but only using the most liquid assets.

  • Above 1 is considered healthy but always compare Nykode to the Biotechnology industry mean.
  • A Quick Ratio of 6.15 means the company can pay off kr6.15 for each kr1 in debt (using most liquid assets).

Let's take a look of the Quick Ratio trends of Nykode Therapeutics ASA:

  • The MRQ is 6.147. The company is very able to pay all its short-term debts with the most liquid assets. +2
  • The TTM is 7.931. The company is very able to pay all its short-term debts with the most liquid assets. +2
Trends
Current periodCompared to+/- 
MRQ6.147TTM7.931-1.784
TTM7.931YOY20.333-12.402
TTM7.9315Y13.362-5.431
5Y13.36210Y13.3620.000
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ6.1474.284+1.863
TTM7.9314.664+3.267
YOY20.3334.787+15.546
5Y13.3625.218+8.144
10Y13.3625.182+8.180

1.4. Solvency of Nykode Therapeutics ASA.

1.3. Liquidity
1.4.1. Debt to Asset Ratio

Measures how much % of Nykode assets are financed with debt.

  • Below 1 (100%) is considered healthy but always compare Nykode to Biotechnology industry mean.
  • A Debt to Asset Ratio of 0.27 means that Nykode assets are financed with 26.8% credit (debt) and the remaining percentage (100% - 26.8%) is financed by its owners/shareholders. 

Let's take a look of the Debt to Asset Ratio trends of Nykode Therapeutics ASA:

  • The MRQ is 0.268. The company is very able to pay all its debts by selling its assets. +2
  • The TTM is 0.259. The company is very able to pay all its debts by selling its assets. +2
Trends
Current periodCompared to+/- 
MRQ0.268TTM0.259+0.009
TTM0.259YOY0.213+0.046
TTM0.2595Y0.224+0.035
5Y0.22410Y0.2240.000
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ0.2680.278-0.010
TTM0.2590.277-0.018
YOY0.2130.306-0.093
5Y0.2240.367-0.143
10Y0.2240.403-0.179
1.4.2. Debt to Equity Ratio

Measures if Nykode is able to pay off its debts by using shareholders equity.

  • Below 2 is considered healthy but always compare Nykode to the Biotechnology industry mean.
  • A Debt to Equity ratio of 36.6% means that company has kr0.37 debt for each kr1 in shareholders equity.

Let's take a look of the Debt to Equity Ratio trends of Nykode Therapeutics ASA:

  • The MRQ is 0.366. The company is very able to pay all its debts with equity. +2
  • The TTM is 0.350. The company is very able to pay all its debts with equity. +2
Trends
Current periodCompared to+/- 
MRQ0.366TTM0.350+0.016
TTM0.350YOY0.271+0.079
TTM0.3505Y0.293+0.058
5Y0.29310Y0.2930.000
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ0.3660.315+0.051
TTM0.3500.317+0.033
YOY0.2710.319-0.048
5Y0.2930.403-0.110
10Y0.2930.462-0.169

2. Market Valuation of Nykode Therapeutics ASA

2. Earnings Per Share
2.1. Price to Earnings Ratio

Measures how much money you pay for each share for every kr1 in earnings Nykode generates.

  • Above 15 is considered overpriced but always compare Nykode to the Biotechnology industry mean.
  • A PE ratio of -48.14 means the investor is paying kr-48.14 for every kr1 in earnings.

Let's take a look of the Price to Earnings Ratio trends of Nykode Therapeutics ASA:

  • The EOD is -54.483. Company is losing money. -2
  • The MRQ is -48.144. Company is losing money. -2
  • The TTM is -27.370. Company is losing money. -2
Trends
Current periodCompared to+/- 
EOD-54.483MRQ-48.144-6.339
MRQ-48.144TTM-27.370-20.774
TTM-27.370YOY-243.632+216.262
TTM-27.3705Y-120.446+93.075
5Y-120.44610Y-120.4460.000
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD-54.483-8.986-45.497
MRQ-48.144-9.792-38.352
TTM-27.370-16.243-11.127
YOY-243.632-20.876-222.756
5Y-120.446-16.665-103.781
10Y-120.446-14.732-105.714
2.2. Price Earnings to Growth Ratio

Measures the predicted future growth of Nykode.

  • Lower is better.
  • A PEG ratio of 1 means the market price of the stock and the expected future earnings are on par.

Let's take a look of the Price Earnings to Growth Ratio trends of Nykode Therapeutics ASA:

  • The MRQ is 116.746. Seems overpriced? -1
  • The TTM is 193.869. Seems overpriced? -1
Trends
Current periodCompared to+/- 
MRQ116.746TTM193.869-77.123
TTM193.869YOY-1,740.375+1,934.244
TTM193.8695Y-773.253+967.122
5Y-773.25310Y-773.2530.000
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ116.746-0.032+116.778
TTM193.8690.004+193.865
YOY-1,740.3750.016-1,740.391
5Y-773.2530.006-773.259
10Y-773.2530.003-773.256

2. Book Value per Share
2.3. Price to Book Ratio

Measures if the stock price of Nykode is to cheap or to expensive compared to its book value.

  • At or below 1 is considered healthy (always compare to Biotechnology industry mean).
  • A PB ratio of 4.29 means the investor is paying kr4.29 for each kr1 in book value.

Let's take a look of the Price to Book Ratio trends of Nykode Therapeutics ASA:

  • The EOD is 4.854. Neutral. Compare to industry.
  • The MRQ is 4.289. Neutral. Compare to industry.
  • The TTM is 7.065. Seems overpriced? -1
Trends
Current periodCompared to+/- 
EOD4.854MRQ4.289+0.565
MRQ4.289TTM7.065-2.776
TTM7.065YOY12.926-5.860
TTM7.0655Y8.885-1.820
5Y8.88510Y8.8850.000
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD4.8541.835+3.019
MRQ4.2892.006+2.283
TTM7.0652.774+4.291
YOY12.9263.453+9.473
5Y8.8852.713+6.172
10Y8.8852.402+6.483
2. Total Gains per Share

3. Summary

3.1. Key Performance Indicators

The key performance indicators of Nykode Therapeutics ASA compared to the Most Recent Quarter (MRQ).

 End of day+/-Most Recent QuarterTrailing 12 Months+/-Year-Over-Year+/-5 Year+/-10 Year+/-
Book Value Change Per Share---0.4680.041-1232%1.217-138%0.622-175%0.622-175%
Book Value Growth--0.8880.897-1%0.918-3%0.908-2%0.908-2%
Book Value Per Share--5.5956.118-9%5.718-2%5.323+5%5.323+5%
Book Value Per Share Growth---0.0840.003-3367%0.202-141%0.102-182%0.102-182%
Current Ratio--6.1477.653-20%18.516-67%12.483-51%12.483-51%
Debt To Asset Ratio--0.2680.259+3%0.213+26%0.224+20%0.224+20%
Debt To Equity Ratio--0.3660.350+5%0.271+35%0.293+25%0.293+25%
Dividend Per Share----0%-0%-0%-0%
Eps---0.499-0.165-67%1.209-141%0.435-215%0.435-215%
Eps Growth---0.412-0.373-9%-6.346+1439%-3.360+715%-3.360+715%
Gross Profit Margin--1.0001.0000%1.0000%1.0000%1.0000%
Net Profit Margin---22.978-8.928-61%-6.863-70%-7.018-69%-7.018-69%
Operating Margin---30.716-11.408-63%-7.476-76%-8.393-73%-8.393-73%
Operating Ratio---4.457-100%8.398-100%5.713-100%5.713-100%
Pb Ratio4.854+12%4.2897.065-39%12.926-67%8.885-52%8.885-52%
Pe Ratio-54.483-13%-48.144-27.370-43%-243.632+406%-120.446+150%-120.446+150%
Peg Ratio--116.746193.869-40%-1740.375+1591%-773.253+762%-773.253+762%
Price Per Share27.160+12%24.00044.123-46%73.918-68%52.462-54%52.462-54%
Price To Total Gains Ratio-58.063-13%-51.308-81.960+60%-297.194+479%-189.577+269%-189.577+269%
Profit Growth---93.948-90.906-3%-110.207+17%-100.556+7%-100.556+7%
Quick Ratio--6.1477.931-22%20.333-70%13.362-54%13.362-54%
Return On Assets---0.065-0.041-37%0.150-144%0.004-1677%0.004-1677%
Return On Equity---0.089-0.056-38%0.194-146%0.011-948%0.011-948%
Revenue Growth--0.505-0.354+170%-11.472+2371%-5.913+1271%-5.913+1271%
Total Gains Per Share---0.4680.041-1232%1.217-138%0.622-175%0.622-175%
Total Gains Per Share Growth---0.459-1.608+250%-7.800+1600%-4.704+925%-4.704+925%
Usd Book Value--167165428.053182781762.637-9%170839874.430-2%159036685.717+5%159036685.717+5%
Usd Book Value Change Per Share---0.0480.004-1232%0.125-138%0.064-175%0.064-175%
Usd Book Value Per Share--0.5760.630-9%0.589-2%0.548+5%0.548+5%
Usd Dividend Per Share----0%-0%-0%-0%
Usd Eps---0.051-0.017-67%0.125-141%0.045-215%0.045-215%
Usd Price Per Share2.797+12%2.4724.545-46%7.614-68%5.404-54%5.404-54%
Usd Profit---14894849.673-9990752.929-33%35062666.192-142%10287571.793-245%10287571.793-245%
Usd Revenue--648211.0549613129.977-93%54643041.444-99%28558298.409-98%28558298.409-98%
Usd Total Gains Per Share---0.0480.004-1232%0.125-138%0.064-175%0.064-175%
 EOD+2 -3MRQTTM+8 -24YOY+8 -245Y+11 -2110Y+11 -21

3.2. Fundamental Score

Let's check the fundamental score of Nykode Therapeutics ASA based on Penke's default stock scanner.

Penke's Stock Scanner

  
  
IndicatorConditionValue
Price to Earnings Ratio (EOD)Between0-15-54.483
Price to Book Ratio (EOD)Between0-14.854
Net Profit Margin (MRQ)Greater than0-22.978
Operating Margin (MRQ)Greater than0-30.716
Quick Ratio (MRQ)Greater than16.147
Current Ratio (MRQ)Greater than16.147
Debt to Asset Ratio (MRQ)Less than10.268
Debt to Equity Ratio (MRQ)Less than10.366
Return on Equity (MRQ)Greater than0.15-0.089
Return on Assets (MRQ)Greater than0.05-0.065
Total4/10 (40.0%)

3.3. Technical Score

Let's check the technical score of Nykode Therapeutics ASA based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than5053.214
Ma 20Greater thanMa 5026.875
Ma 50Greater thanMa 10026.157
Ma 100Greater thanMa 20029.847
OpenGreater thanClose25.300
Total2/5 (40.0%)



Latest Balance Sheet

Balance Sheet of 2022-09-30. Currency in USD. All numbers in thousands.

Summary
Total Assets228,314
Total Liabilities61,203
Total Stockholder Equity167,111
 As reported
Total Liabilities 61,203
Total Stockholder Equity+ 167,111
Total Assets = 228,314

Assets

Total Assets228,314
Total Current Assets218,619
Long-term Assets218,619
Total Current Assets
Net Receivables 6,598
Total Current Assets  (as reported)218,619
Total Current Assets  (calculated)6,598
+/- 212,021
Long-term Assets
Property Plant Equipment 9,214
Intangible Assets 32
Long-term Assets  (as reported)0
Long-term Assets  (calculated)9,246
+/- 9,246

Liabilities & Shareholders' Equity

Total Current Liabilities35,566
Long-term Liabilities-
Total Stockholder Equity167,111
Total Current Liabilities
Accounts payable 5,274
Other Current Liabilities 20,109
Total Current Liabilities  (as reported)35,566
Total Current Liabilities  (calculated)25,383
+/- 10,183
Long-term Liabilities
Long term Debt Total 4,126
Long-term Liabilities  (as reported)0
Long-term Liabilities  (calculated)4,126
+/- 4,126
Total Stockholder Equity
Common Stock334
Retained Earnings 76,918
Capital Surplus 82,314
Other Stockholders Equity 7,545
Total Stockholder Equity (as reported)167,111
Total Stockholder Equity (calculated)167,111
+/-0
Other
Cash And Equivalents212,021
Cash and Short Term Investments 212,021
Common Stock Shares Outstanding 290,069
Liabilities and Stockholders Equity 228,314
Net Tangible Assets 167,079



Balance Sheet

Currency in USD. All numbers in thousands.

 Trend2022-09-302022-06-302022-03-312021-12-312021-09-302021-06-302021-03-312020-12-312020-09-30
> Total Assets 
19,339
230,028
223,854
212,052
202,650
265,556
254,073
238,832
228,314
228,314238,832254,073265,556202,650212,052223,854230,02819,339
   > Total Current Assets 
19,180
229,032
222,948
211,260
201,734
255,858
244,076
228,875
218,619
218,619228,875244,076255,858201,734211,260222,948229,03219,180
       Cash And Cash Equivalents 
18,017
183,851
179,738
174,378
172,645
216,231
225,681
213,279
0
0213,279225,681216,231172,645174,378179,738183,85118,017
       Short-term Investments 
0
24,944
23,748
20,774
16,319
12,169
12,234
10,035
0
010,03512,23412,16916,31920,77423,74824,9440
       Net Receivables 
0
20,087
19,462
16,108
12,770
26,155
6,161
5,561
6,598
6,5985,5616,16126,15512,77016,10819,46220,0870
       Other Current Assets 
0
-1
0
0
0
0
12,234
0
0
0012,2340000-10
   > Long-term Assets 
0
0
906
792
917
9,698
9,997
9,957
0
09,9579,9979,69891779290600
       Property Plant Equipment 
116
408
323
230
374
9,165
9,453
9,469
9,214
9,2149,4699,4539,165374230323408116
       Intangible Assets 
33
32
32
32
32
32
32
32
32
323232323232323233
> Total Liabilities 
2,501
51,178
50,242
43,552
40,475
71,501
65,432
57,750
61,203
61,20357,75065,43271,50140,47543,55250,24251,1782,501
   > Total Current Liabilities 
2,500
13,181
13,746
9,602
10,923
31,367
31,129
27,026
35,566
35,56627,02631,12931,36710,9239,60213,74613,1812,500
       Accounts payable 
0
1,612
8,984
5,564
7,037
2,746
6,985
5,394
5,274
5,2745,3946,9852,7467,0375,5648,9841,6120
       Other Current Liabilities 
0
1,613
47
161
495
17,975
18,062
17,778
20,109
20,10917,77818,06217,975495161471,6130
   > Long-term Liabilities 
0
0
36,496
33,950
29,552
40,134
34,303
30,724
0
030,72434,30340,13429,55233,95036,49600
       Long term Debt Total 
0
8
8
7
10
5,820
5,639
4,798
4,126
4,1264,7985,6395,820107880
       Other Liabilities 
0
37,989
36,488
33,943
29,542
34,314
28,664
25,926
21,511
21,51125,92628,66434,31429,54233,94336,48837,9890
       Deferred Long Term Liability 
0
551
0
0
0
478
0
0
0
0004780005510
> Total Stockholder Equity
16,838
178,850
173,612
168,500
162,175
194,055
188,641
181,082
167,111
167,111181,082188,641194,055162,175168,500173,612178,85016,838
   Common Stock
316
327
328
329
330
333
334
334
334
334334334333330329328327316
   Retained Earnings 
-41,623
116,869
110,362
104,114
96,686
107,455
100,557
91,808
76,918
76,91891,808100,557107,45596,686104,114110,362116,869-41,623
   Capital Surplus 
58,145
60,348
60,783
61,224
61,356
81,526
82,006
82,314
82,314
82,31482,31482,00681,52661,35661,22460,78360,34858,145
   Treasury Stock000000000
   Other Stockholders Equity 
0
1,306
2,139
2,833
3,803
4,741
5,744
6,626
7,545
7,5456,6265,7444,7413,8032,8332,1391,3060



Balance Sheet

Currency in USD. All numbers in thousands.




Cash Flow

Currency in USD. All numbers in thousands.




Income Statement

Currency in USD. All numbers in thousands.


Latest Income Statement (annual, 2021-12-31)

Gross Profit (+$)
totalRevenue33,963
Cost of Revenue--
Gross Profit-33,963
 
Operating Income (+$)
Gross Profit-
Operating Expense-44,738
Operating Income-10,775-44,738
 
Operating Expense (+$)
Research Development16,300
Selling General Administrative16,846
Selling And Marketing Expenses-
Operating Expense44,73833,146
 
Net Interest Income (+$)
Interest Income342
Interest Expense-130
Net Interest Income166212
 
Pretax Income (+$)
Operating Income-10,775
Net Interest Income166
Other Non-Operating Income Expenses-
Income Before Tax (EBT)-11,117-10,775
EBIT - interestExpense = -10,905
-11,117
-9,283
Interest Expense130
Earnings Before Interest and Taxes (ebit)-10,775-10,987
Earnings Before Interest and Taxes (ebitda)-10,252
 
After tax Income (+$)
Income Before Tax-11,117
Tax Provision--1,704
Net Income From Continuing Ops-9,414-9,413
Net Income-9,413
Net Income Applicable To Common Shares-9,414
 
Non-recurring Events
Discontinued Operations-
Extraordinary Items-
Effect of Accounting Charges-
Other Items-
Non Recurring-
Other Operating Expenses28,295
Total Other Income/Expenses Net--166
 

Comments

Join the conversation.

Leave a comment

Stay informed with my latest content.

Subscribe to my newsletter and receive an email as soon as I add content to PenkeTrading.com.


By clicking Register, you agree to the General Terms and Conditions.
Penke's Market Notifications
NTG.XETRA
now

I found you a STOCH Bearish Reversal Divergence on the daily chart of NTG.XETRA.

NTG.XETRA Daily Candlestick Chart
JUN3.XETRA
now

I found you a Overbought RSI (Relative Strength Index) on the daily chart of JUN3.XETRA.

JUN3.XETRA Daily Candlestick Chart
FEV.XETRA
3 minutes ago

I found you a Golden Cross on the daily chart of FEV.XETRA.

FEV.XETRA Daily Candlestick Chart
EUN2.XETRA
7 minutes ago

I found you a Golden Cross on the daily chart of EUN2.XETRA.

EUN2.XETRA Daily Candlestick Chart
DBPD.XETRA
7 minutes ago

I found you a Death Cross on the daily chart of DBPD.XETRA.

DBPD.XETRA Daily Candlestick Chart
V50A.XETRA
8 minutes ago

I found you a Golden Cross on the daily chart of V50A.XETRA.

V50A.XETRA Daily Candlestick Chart
ETDD.XETRA
9 minutes ago

I found you a Golden Cross on the daily chart of ETDD.XETRA.

ETDD.XETRA Daily Candlestick Chart
CEC.XETRA
11 minutes ago

I found you a Overbought RSI (Relative Strength Index) on the daily chart of CEC.XETRA.

CEC.XETRA Daily Candlestick Chart
XMLC.XETRA
12 minutes ago

I found you a Golden Cross on the daily chart of XMLC.XETRA.

XMLC.XETRA Daily Candlestick Chart
E4C.XETRA
13 minutes ago

I found you a Golden Cross on the daily chart of E4C.XETRA.

E4C.XETRA Daily Candlestick Chart
TULV.TO
13 minutes ago

I found you a Golden Cross on the daily chart of TULV.TO.

TULV.TO Daily Candlestick Chart
ZAL.XETRA
13 minutes ago

I found you a STOCH Bearish Reversal Divergence on the daily chart of ZAL.XETRA.

ZAL.XETRA Daily Candlestick Chart
LOTA.V
13 minutes ago

I found you a STOCH Bearish Hidden Divergence on the daily chart of LOTA.V.

LOTA.V Daily Candlestick Chart
SPTE.LSE
15 minutes ago

I found you a Oversold RSI (Relative Strength Index) on the daily chart of SPTE.LSE.

SPTE.LSE Daily Candlestick Chart
SHP1.LSE
15 minutes ago

I found you a Overbought RSI (Relative Strength Index) on the daily chart of SHP1.LSE.

SHP1.LSE Daily Candlestick Chart
PLTS.LSE
15 minutes ago

I found you a Death Cross on the daily chart of PLTS.LSE.

PLTS.LSE Daily Candlestick Chart
PDD.LSE
15 minutes ago

I found you a Overbought RSI (Relative Strength Index) on the daily chart of PDD.LSE.

PDD.LSE Daily Candlestick Chart
NRJL.LSE
15 minutes ago

I found you a Death Cross on the daily chart of NRJL.LSE.

NRJL.LSE Daily Candlestick Chart
IEEU.LSE
16 minutes ago

I found you a Overbought RSI (Relative Strength Index) on the daily chart of IEEU.LSE.

IEEU.LSE Daily Candlestick Chart
EUSR.LSE
17 minutes ago

I found you a Overbought RSI (Relative Strength Index) on the daily chart of EUSR.LSE.

EUSR.LSE Daily Candlestick Chart
APEX.LSE
18 minutes ago

I found you a Overbought RSI (Relative Strength Index) on the daily chart of APEX.LSE.

APEX.LSE Daily Candlestick Chart
3SRR.LSE
18 minutes ago

I found you a RSI Bullish Reversal Divergence on the daily chart of 3SRR.LSE.

3SRR.LSE Daily Candlestick Chart
3SHE.LSE
18 minutes ago

I found you a Overbought RSI (Relative Strength Index) on the daily chart of 3SHE.LSE.

3SHE.LSE Daily Candlestick Chart